Finney Capital
Overview
Finney Capital is a venture capital firm investing in early-stage companies in biotechnology and related sectors. The firm focuses on areas such as biotechnology, biopharmaceuticals, biotech tools, sustainable food, and renewable energy. Finney Capital's investment strategy targets seed and early-stage companies, particularly those in Series A funding rounds. The firm's geographical focus is primarily on the United States. Finney Capital's portfolio includes investments in companies like Orion Genomics, which received Series A funding in December 1998. The firm's managing director, Michael Finney, has a background in the life sciences industry, having served as a founder, director, and investor in various life sciences companies since 1986. He holds an A.B. in biochemical sciences from Harvard University and a Ph.D. in biology (genetics) from the Massachusetts Institute of Technology. Under his leadership, Finney Capital has been involved in investments in companies such as Vaxart, S2 Genomics, Chimera Bioengineering, and Nanotech Bio. The firm's investment philosophy emphasizes supporting innovative companies that aim to address unmet needs in biotechnology and related fields.
Reach Finney Capital directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Finney Capital
What sectors does Finney Capital invest in?
Finney Capital invests in Renewable Energy, Biotechnology, Biopharmaceuticals, Sustainable Food and Biotech Tools, and is based in California, United States. Finney Capital is listed as a venture capital in the ConnectSafely investor database.
What stage does Finney Capital invest at?
Finney Capital backs companies at Seed, Early Stage and Series A.
Which regions does Finney Capital invest in?
Finney Capital invests across United States.
Last updated · Source: ConnectSafely investor database